Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ARNA Stock Summary
In the News
Pfizer closes $6.7 billion acquisition of Arena Pharmaceuticals
Shares of Pfizer Inc. PFE, +2.32% were up 2.0% in trading on Friday after the company said it closed its $6.7 billion acquisition of Arena Pharmaceuticals Inc. Arena is developing treatments for immuno-inflammatory diseases like ulcerative colitis and atopic dermatitis. It has said it expects to share data from a Phase 3 clinical trial testing one of those experimental therapies, etrasimod, in ulcerative colitis patients during the first quarter of his year.
7 Biotech Stocks With Key Catalysts in March
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on InvestorPlace.
11 Marijuana Stocks on Fire to Close February
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we make our way through 2022.
Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus
Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.
Top 3 weed stocks to put on your watch list this year
The marijuana industry has seen sharp growth year on year.
Pharma Giants Go After $10 Billion Market With RSV Drugs
GlaxoSmithKline PLC ( GSK , Financial), Pfizer Inc. ( PFE , Financial) and Johnson & Johnson ( JNJ , Financial) should all know about mid-year if the shots they're developing for a common and potentially fatal virus is effective. No, the it isn't for Covid-19, but for respiratory syncytial virus, which causes an estimated 177,000 hospitalizations among older adults each year and 58,000 in children under five.
Cannabis Watch: Pfizer's Arena Pharma deal may lead drug company to a cannabis-based treatment
Pfizer Inc.'s presentation of its pending $6.7 billion acquisition of clinical-stage drug company Arena Pharmaceuticals Inc. contained no mention of cannabis.
Should You Buy Arena Pharmaceuticals, Inc. (ARNA) After Golden Cross?
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Abivax: Potentially The Next Arena Pharmaceuticals, Most Ideal Big Pharma M&A Target In 2022
Arena Pharmaceuticals got acquired by Pfizer for US$ 6.7 Bn (~100% valuation) on December 12th. As a result, the market for late-stage oral IBD candidates that big pharma can acquire is thinning.
Pfizer (PFE) to Buy Arena, Boost Immuno-Inflammatory Pipeline
Pfizer (PFE) signs an agreement to acquire Arena Pharmaceuticals for $6.7 billion in cash. Stock rises.
ARNA Financial details
ARNA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.65 | 0.38 | 15.6 | 0.01 | 0 | |
Net income per share | -2.77 | -0.62 | 7.69 | -7.39 | -11.33 | |
Operating cash flow per share | -2.02 | -2.81 | 11 | -6.45 | -8.25 | |
Free cash flow per share | -2.02 | -2.83 | 10.91 | -6.46 | -9.55 | |
Cash per share | 7.49 | 9.47 | 14.31 | 20.16 | 10.05 | |
Book value per share | 6.28 | 12.89 | 20.73 | 19.73 | 12.29 | |
Tangible book value per share | 6.28 | 12.89 | 20.73 | 19.73 | 12.29 | |
Share holders equity per share | 6.28 | 12.89 | 20.73 | 19.73 | 12.29 | |
Interest debt per share | 0.31 | 0.19 | 0.17 | 0.16 | 0.83 | |
Market cap | 1.12B | 1.83B | 2.35B | 4.21B | 5.09B | |
Enterprise value | 1.02B | 1.72B | 2.15B | 4.03B | 4.91B | |
P/E ratio | -12.26 | -62.32 | 5.91 | -10.4 | -8.2 | |
Price to sales ratio | 52.52 | 101.96 | 2.91 | 13.19K | 94.26K | |
POCF ratio | -16.82 | -13.86 | 4.13 | -11.92 | -11.26 | |
PFCF ratio | -16.79 | -13.79 | 4.16 | -11.89 | -9.73 | |
P/B Ratio | 5.41 | 3.02 | 2.19 | 3.89 | 7.56 | |
PTB ratio | 5.41 | 3.02 | 2.19 | 3.89 | 7.56 | |
EV to sales | 47.97 | 95.93 | 2.67 | 12.65K | 90.86K | |
Enterprise value over EBITDA | -12.64 | -13.24 | 4.18 | -10.18 | -8.06 | |
EV to operating cash flow | -15.36 | -13.04 | 3.79 | -11.42 | -10.86 | |
EV to free cash flow | -15.33 | -12.97 | 3.82 | -11.4 | -9.38 | |
Earnings yield | -0.08 | -0.02 | 0.17 | -0.1 | -0.12 | |
Free cash flow yield | -0.06 | -0.07 | 0.24 | -0.08 | -0.1 | |
Debt to equity | 0.02 | 0.01 | 0 | 0 | 0.06 | |
Debt to assets | 0.01 | 0 | 0 | 0 | 0.05 | |
Net debt to EBITDA | 1.2 | 0.83 | -0.38 | 0.44 | 0.3 | |
Current ratio | 3.89 | 15.4 | 16.9 | 19.62 | 8.59 | |
Interest coverage | -15.03 | -25.42 | 100.76 | -94.33 | -147.22 | |
Income quality | 0.73 | 4.5 | 1.43 | 0.87 | 0.73 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.42 | 2.65 | 0.1 | 323.51 | 2.34K | |
Research and developement to revenue | 3.33 | 6.4 | 0.29 | 1.01K | 7.77K | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.01 | -0.01 | 0 | 0.16 | |
Capex to revenue | -0.01 | -0.04 | -0.01 | -2.57 | -1.31K | |
Capex to depreciation | -0.03 | -0.18 | -1.49 | -0.21 | -18.33 | |
Stock based compensation to revenue | 0.37 | 1.09 | 0.07 | 187.84 | 1.3K | |
Graham number | 19.78 | 13.46 | 59.88 | 57.27 | 55.98 | |
ROIC | -0.35 | -0.04 | 0.34 | -0.4 | -0.82 | |
Return on tangible assets | -0.27 | -0.04 | 0.34 | -0.34 | -0.79 | |
Graham Net | 3.81 | 7.84 | 12.34 | 18.15 | 8.02 | |
Working capital | 208.95M | 430.81M | 714.97M | 1.08B | 503.15M | |
Tangible asset value | 207.14M | 606.26M | 1.07B | 1.08B | 673.24M | |
Net current asset value | 149.15M | 380.08M | 657.28M | 1.03B | 458M | |
Invested capital | 0.02 | 0.01 | 0 | 0 | 0.06 | |
Average receivables | 17.27M | 9.73M | 3.37M | 827K | 0 | |
Average payables | 3.79M | 3.9M | 6.12M | 9.02M | 12.65M | |
Average inventory | 3.35M | 0 | 0 | 0 | 0 | |
Days sales outstanding | 246.02 | 103.3 | 0.75 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 1.48 | 3.53 | 487.56 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.44 | -0.05 | 0.37 | -0.37 | -0.92 | |
Capex per share | 0 | -0.01 | -0.09 | -0.01 | -1.3 |
Quarterly Fundamentals Overview
Last date of statement is 2021-12-31 for Q4
Metric | History | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -2.1 | -1.98 | -2.4 | -3.21 | -2.55 | |
Operating cash flow per share | -1.83 | -2.01 | -1.54 | -1.92 | -1.96 | |
Free cash flow per share | -1.83 | -2.01 | -1.55 | -3.07 | -1.97 | |
Cash per share | 18.94 | 18.21 | 15.98 | 12.62 | 8.97 | |
Book value per share | 18.54 | 18.17 | 15.98 | 13.1 | 10.97 | |
Tangible book value per share | 18.54 | 18.17 | 15.98 | 13.1 | 10.97 | |
Share holders equity per share | 18.54 | 18.17 | 15.98 | 13.1 | 10.97 | |
Interest debt per share | 0.09 | 0.75 | 0.73 | 0.71 | 0.69 | |
Market cap | 4.48B | 4.15B | 4.15B | 3.64B | 5.7B | |
Enterprise value | 4.3B | 3.76B | 3.67B | 3.3B | 5.52B | |
P/E ratio | -9.16 | -8.76 | -7.09 | -4.64 | -9.11 | |
Price to sales ratio | 121.03K | 0 | 0 | 0 | 105.64K | |
POCF ratio | -42.1 | -34.57 | -44.18 | -30.94 | -47.34 | |
PFCF ratio | -42.04 | -34.54 | -44.08 | -19.38 | -47.13 | |
P/B Ratio | 4.14 | 3.82 | 4.27 | 4.55 | 8.47 | |
PTB ratio | 4.14 | 3.82 | 4.27 | 4.55 | 8.47 | |
EV to sales | 116.33K | 0 | 0 | 0 | 102.24K | |
Enterprise value over EBITDA | -35.84 | -32.01 | -25.51 | -16.97 | -35.93 | |
EV to operating cash flow | -40.46 | -31.33 | -39.16 | -28.01 | -45.82 | |
EV to free cash flow | -40.41 | -31.31 | -39.08 | -17.55 | -45.62 | |
Earnings yield | -0.03 | -0.03 | -0.04 | -0.05 | -0.03 | |
Free cash flow yield | -0.02 | -0.03 | -0.02 | -0.05 | -0.02 | |
Debt to equity | 0 | 0.04 | 0.04 | 0.05 | 0.06 | |
Debt to assets | 0 | 0.04 | 0.04 | 0.05 | 0.05 | |
Net debt to EBITDA | 1.45 | 3.31 | 3.27 | 1.77 | 1.19 | |
Current ratio | 19.62 | 23.61 | 15.28 | 14.82 | 8.59 | |
Interest coverage | -123.45 | 0 | -137.38 | -188.64 | -153.99 | |
Income quality | 0.87 | 1.01 | 0.64 | 0.6 | 0.77 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 943.24 | 0 | 0 | 0 | 638.89 | |
Research and developement to revenue | 2.71K | 0 | 0 | 0 | 2.04K | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0.6 | 0 | |
Capex to revenue | -3.68 | 0 | 0 | 0 | -9.87 | |
Capex to depreciation | -0.14 | -0.1 | -0.21 | -72.25 | -0.56 | |
Stock based compensation to revenue | 544.68 | 0 | 0 | 0 | 338.26 | |
Graham number | 29.57 | 28.45 | 29.39 | 30.76 | 25.09 | |
ROIC | -0.13 | -0.13 | -0.14 | -0.22 | -0.21 | |
Return on tangible assets | -0.1 | -0.1 | -0.13 | -0.22 | -0.2 | |
Graham Net | 17.05 | 16.58 | 14.11 | 10.98 | 7.15 | |
Working capital | 1.08B | 1.07B | 925.6M | 737.57M | 503.15M | |
Tangible asset value | 1.08B | 1.09B | 971.08M | 800.72M | 673.24M | |
Net current asset value | 1.03B | 1.02B | 876.86M | 690.61M | 458M | |
Invested capital | 0 | 0.04 | 0.04 | 0.05 | 0.06 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 9.84M | 10.78M | 6.67M | 5.36M | 10.12M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.11 | -0.11 | -0.15 | -0.25 | -0.23 | |
Capex per share | 0 | 0 | 0 | -1.15 | -0.01 |
ARNA Frequently Asked Questions
What is Arena Pharmaceuticals, Inc. stock symbol ?
Arena Pharmaceuticals, Inc. is a US stock , located in San diego of California and trading under the symbol ARNA
Is Arena Pharmaceuticals, Inc. buy or a sell ?
3 stock analysts have 3 predictions with a medium analyst target price of $94. The lowest prediction is $90 and the highest is $100
What is ARNA stock prediction ?
What is Arena Pharmaceuticals, Inc. stock quote today ?
Arena Pharmaceuticals, Inc. stock price is $99.99 today.
Is Arena Pharmaceuticals, Inc. stock public?
Yes, Arena Pharmaceuticals, Inc. is a publicly traded company.